Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristina Pilipović has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    1,8-Cineole (Eucalyptol) in Neurodegeneration: From Pharmacological Mechanisms to Therapeutic Applications

    by Tamara Janković, Kristina Pilipović, Nika Gržeta Krpan, Jelena Rajič Bumber, Silvestar Mežnarić, Ana Pelčić, Petra Dolenec, Tea Ćelić, Jasenka Mršić-Pelčić

    Neurodegenerative diseases represent an enormous global burden, and due to the lack of effective therapies, the number of affected individuals continues to rise, placing a significant pressure on patients and their families. Phytochemicals such as terpenes are a group of compounds that have the potential to provide long-term neuroprotective effects by targeting multiple pathobiological pathways and supporting the brain’s natural defense mechanisms. 1,8-cineole (eucalyptol) is a monoterpene known for its anti-inflammatory and antioxidant properties, mainly utilized in the respiratory system. However, due to its ability to cross the blood–brain barrier, beneficial effects have been observed in the central nervous system. Here we examine the pharmacological mechanisms and neuroprotective potential of 1,8-cineole in the nervous tissue. Studies have shown that 1,8-cineole has the potential to suppress neuroinflammation and reduce glial activation, activate antioxidant defense mechanisms and scavenge reactive oxygen species. Additionally, 1,8-cineole has been shown to modulate central neurotransmission and synaptic plasticity, inhibit apoptotic neuronal death and regulate ion channels involved in pain modulation. This review aims to examine the therapeutic potential of 1,8-cineole in the most prevalent neurodegenerative diseases in the population, such as Alzheimer’s and Parkinson’s diseases, as well as brain injuries, including ischemic stroke and traumatic brain injury, which may lead to neurodegeneration. We also explore the potential benefits of 1,8-cineole for anxiety and depression, which occur as early symptoms or common complications of neurodegenerative diseases. Given the need for novel therapeutic approaches, combination therapies that utilize the therapeutic potential of phytochemicals, such as 1,8-cineole, may enable more effective targeting of the multiple, interconnected pathobiological processes underlying neurodegenerative diseases.

  • Open Access

    Nanotube-Assisted Motor Neuron and Neuromuscular Junction Stabilization in Spinal Muscular Atrophy: A Hypothesis for Adjunctive Therapy

    by Almir Fajkić, Andrej Belančić, Kristina Pilipović, Valentino Rački, Silvestar Mežnarić, Tamara Janković, Elvira Meni Maria Gkrinia, Dinko Vitezić, Jasenka Mršić-Pelčić

    Spinal muscular atrophy (SMA) therapies that restore SMN expression improve survival and motor function but often fail to fully stabilize distal motor units or sustain endurance. We propose a hypothesis-driven adjunctive approach, intended to complement SMN-restoring therapies, in which localized nanotube-enabled interfaces acting at or near the distal motor unit and neuromuscular junction enhance neuromuscular transmission reliability in surviving, remodeled motor units. The model predicts a temporal cascade: improved junctional reliability and reduced activity-dependent failure, followed by consistent motor unit output across repeated activation, and ultimately, enhanced endurance and functional reserve. Phenotype-specific responsiveness identifies patients most likely to benefit, specifically those with preserved-but-limited residual motor unit substrate accompanied by measurable neuromuscular junction instability. Drawing on shared mechanisms from ALS, spinal cord injury, and other neuromuscular disorders, we discuss mechanistic, translational, safety, regulatory, and ethical considerations. This framework links objective physiological constructs to functional outcomes, offering a mechanistically grounded path for adjunctive therapy development in SMA and related conditions.


  • Open Access

    From Brain Organoids to Translational Neurology: Exploring Neuroprotective Targets and Molecular Approaches in Perinatal Brain Injury

    by Anja Harej Hrkać, Ana Pelčić, Silvestar Mežnarić, Jasenka Mršić-Pelčić, Kristina Pilipović

    Perinatal brain injury (PBI) is a leading cause of long-term neurological deficits in newborns, yet effective therapies are limited. At the cellular level, PBI involves hypoxic–ischemic stress, neuroinflammation, oxidative damage, excitotoxicity, and disrupted neurovascular and glial development. Traditional animal models and 2D cultures cannot fully capture the spatiotemporal complexity of the developing human brain, highlighting the need for more physiologically relevant systems. Human brain organoids have emerged as advanced three-dimensional models that recapitulate region-specific cytoarchitecture, neuronal and glial differentiation, and early circuit formation. They enable modeling of hypoxic–ischemic and inflammatory insults, allowing for the study of injury-induced changes in neurogenesis, gliogenesis, synaptic development, and cell interactions. Organoids facilitate identification of molecular pathways involved in injury and repair, supporting therapeutic target discovery. Using patient-derived induced pluripotent stem cells, organoids also allow personalized pharmacogenomic studies to assess genotype-dependent drug responses and toxicity. Despite limitations such as variability, lack of vascularization and immune components, and ethical considerations, brain organoids offer a promising platform to bridge developmental neurobiology and translational therapeutics, paving the way for targeted and individualized interventions in PBI.


  • Open Access

    Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies

    by Petra Dolenec, Goran Pelčić, Kristina Pilipović, Jasenka Mršić-Pelčić, Anja Harej Hrkać

    Glaucoma is increasingly recognized as an ischemic neurodegenerative disorder that extends beyond elevated intraocular pressure (IOP) to involve complex vascular, metabolic, and inflammatory mechanisms. Retinal ganglion cells are particularly vulnerable to ischemia–reperfusion injury, oxidative stress, and chronic neuroinflammation, leading to progressive disconnection from central visual pathways. Current therapies primarily target IOP reduction but fail to address ischemia-driven neurodegeneration or to restore lost neuronal connectivity. Ischemia triggers excitotoxicity, oxidative stress, and a maladaptive inflammatory response involving activated microglia and astrocytes, perpetuating neuronal injury and suppressing intrinsic regenerative capacity. Thus, restoring neural plasticity and mitigating neuroinflammation represent key unmet therapeutic needs. Psychoplastogens are a class of compounds capable of rapidly enhancing structural and functional neuroplasticity and have recently emerged as promising multitarget agents. Compounds such as ketamine, psilocybin, N,N-dimethyltryptamine (DMT), and some newly synthesized non-hallucinogenic analogs act through convergent signaling pathways involving BDNF–TrkB–mTOR, promoting dendritic growth, synaptogenesis, and glial modulation. Beyond their neurotrophic effects, psychoplastogens seem to exert potent immunomodulatory actions. In this review we will explore the interplay between ischemia, neurodegeneration, neuroinflammation, and impaired plasticity in glaucoma, integrating mechanistic insights from cerebral ischemia. We discuss emerging preclinical evidence supporting psychoplastogens as neurorestorative and anti-inflammatory agents, propose their potential application in ocular ischemic neurodegeneration, and outline translational challenges for future studies.

  • Open Access

    Human Induced Pluripotent Stem Cells in Rare Neurological Disorders: Opportunities and Challenges for Disease Modeling and Drug Discovery

    by Anja Harej Hrkać, Valentino Rački, Andrej Belančić, Jasna Kriz, Dinko Vitezić, Jasenka Mršić-Pelčić, Ganesh Acharya, Mukesh Varshney, Kristina Pilipović

    Rare disease is a condition that affects a small fraction of the population. In most cases, it has a known genetic cause but could also be associated with other contributing factors. As the affected individuals may exhibit diverse symptoms due to the genetic and phenotypic heterogeneity, non‐ or misdiagnosis of rare diseases is common. Their low incidence and prevalence present an obstacle to developing new therapies despite a major unmet need with only a few treatment options available. This is particularly relevant to rare neurological disorders as there are major difficulties in studying the mechanisms of initiation and progression of the central nervous system (CNS) disorders. Recent advances in biotechnology, specifically the use of human induced pluripotent stem cells (iPSCs) for modeling diseases, have been instrumental in providing a flexible platform that not only reflects the effects of genetic disturbances on the development of CNS disorders but also is capable of providing insights into complex multifactorial disorders. Whether the human iPSCs are harvested from the affected individuals or using the gene‐editing tools on cells from healthy individuals, valuable models can now be made available for studying these orphan conditions. In this narrative review, we explore the benefits of using human iPSC models over the existing platforms of other primary cell lines and animal models for the disease modeling and drug discovery and discuss the limitations and future aspects of the iPSC use in the investigation of rare neurological disorders.

  • Cytotoxicity Thresholds and Limited Modulation of LPS-Induced Microglial Activation by Croatian Olive Leaf Extracts: A Preliminary Study in a BV-2 Washout Model

    by Kristina Pilipović, Lucia Fabijančić, Iva Kristić, Lara Saftić Martinović

    Objectives: Neuroinflammation, largely mediated by microglial activation, plays a central role in the pathogenesis of neurodegenerative diseases. In this study, we aimed to evaluate olive leaf extracts (OLEs) from three Croatian cultivars (Buža, Oblica, and Leccino) in the context of lipopolysaccharide (LPS)-induced activation of BV-2 microglia. Methods: Extracts were prepared by aqueous maceration and ethanol extraction under conditions compatible with downstream cell-culture use. Total phenolic and flavonoid contents were determined for both extract types, alongside targeted liquid chromatography–mass spectrometry (LC–MS/MS) quantification of major phenolic compounds. Based on compositional analysis, ethanolic extracts were selected for further evaluation, including antioxidant capacity assays [2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)] and assessment of BV-2 microglial responses to LPS, i.e., measurements of cell viability, activation markers (CD86, CD206, iNOS), and selected markers of inflammatory (phospho-p65, Sirt1) and cytoprotective pathways (Nrf2, HSP70). Results: Ethanolic extracts exhibited higher total phenolic and flavonoid contents than aqueous macerates, supported by LC–MS/MS analysis showing increased levels of key constituents such as oleuropein and other flavonoids. Antioxidant activity varied depending on the assay: DPPH activity was comparable across cultivars (p = 0.858), whereas ABTS activity was highest for the Oblica extract (p = 0.0002). Ethanolic extracts were non-cytotoxic at 10 μg/mL, while higher concentrations induced dose-dependent cytotoxicity (p = 0.0001). In BV-2 cells, LPS (1 μg/mL, 3 h) increased CD86 (p = 0.017) and CD206 expression (p < 0.0001), with no change in iNOS levels (p = 0.0697). Short-term, non-cytotoxic pretreatment with ethanolic extracts (10 μg/mL, 3 h) did not significantly alter microglial activation markers or the examined inflammatory and cytoprotective pathways. Conclusion: These findings define the experimental limits under the applied conditions and indicate that compositional richness alone does not necessarily translate into measurable biological effects, supporting further studies with extended exposure and refined dosing.

  • Open Access

    Novel Translational Concept: Axon-to-Muscle Exosomal Signaling as an Emerging Therapeutic Target in Spinal Muscular Atrophy

    by Almir Fajkić, Andrej Belančić, Yun Wah Lam, Valentino Rački, Kristina Pilipović, Tamara Janković, Silvestar Mežnarić, Jasenka Mršić-Pelčić, Dinko Vitezić

    Spinal muscular atrophy (SMA) has transitioned from a uniformly fatal disease to a treatable condition, yet incomplete neuromuscular recovery underscores the limits of current SMN-restorative therapies. Emerging data implicate disrupted axon-to-muscle exosomal signaling as an important, overlooked driver of residual dysfunction. Exosomes, nanovesicles mediating bidirectional neuronal-muscular communication, carry synaptic organizers, trophic factors, and microRNAs essential for neuromuscular junction integrity. SMN deficiency alters exosomal biogenesis and cargo, leading to loss of agrin-MuSK signaling, impaired β-actin transport, and muscle atrophy. Comparative insights from amyotrophic lateral sclerosis and muscular dystrophy reveal that stem-cell-derived or engineered exosomes restore synaptic stability, enhance regeneration, and cross biological barriers safely. Thus, we speculate herein on a translational model integrating exosome-based therapies with existing genetic interventions to achieve durable, systems-level recovery in SMA. Exosomal profiling may further yield minimally invasive biomarkers for disease monitoring and treatment optimization, establishing vesicle-mediated communication as a novel therapeutic axis in neuromuscular medicine.


  • Open Access

    Transforming Spinal Muscular Atrophy: From Pivotal Trials to Real-World Evidence and Future Therapeutic Frontiers in Types 1 and 2

    by Andrej Belančić, Patrick Castillo Eustaquio, Elvira Meni Maria Gkrinia, Valentino Rački, Kristina Pilipović, Dinko Vitezić

    Spinal muscular atrophy (SMA) is a rare, autosomal recessive neuromuscular disorder and a leading genetic cause of infant mortality. The past decade has witnessed a paradigm shift in SMA management with the advent of disease-modifying drugs (DMDs). This narrative review aims to (i) summarize pivotal randomized controlled trials (RCTs) that led to the approval of DMDs for SMA Types 1 and 2; (ii) synthesize real-world evidence on their safety and effectiveness; and (iii) explore emerging therapeutic frontiers, including gene modifiers, predictive biomarkers, prenatal interventions, and combination strategies. Pivotal RCTs and real-world studies demonstrate that onasemnogene abeparvovec (a single-dose gene therapy), nusinersen (an intrathecal antisense oligonucleotide), and risdiplam (an oral SMN2 splicing modifier) each significantly improve survival and motor function milestones compared to natural history in Type 1 and Type 2 SMA, with the majority of treated patients achieving independent sitting and prolonged ventilator-free survival, while safety profiles are generally manageable and distinct for each therapy. Similar outcomes have been demonstrated for presymptomatic patients with SMA. The introduction of DMDs has transformed the prognosis of SMA, particularly for early-onset forms, with robust evidence supporting their efficacy and safety. Continued real-world monitoring and exploration of adjunctive therapies are essential to optimize outcomes across the SMA setting and address unmet needs in non-responders and older patients.


  • Open Access

    Prenatal Management of Spinal Muscular Atrophy in the Era of Genetic Screening and Emerging Opportunities in In Utero Therapy

    by Silvestar Mežnarić, Andrej Belančić, Valentino Rački, Dinko Vitezić, Jasenka Mršić-Pelčić, Kristina Pilipović

    Spinal muscular atrophy (SMA) is a severe autosomal recessive neuromuscular disorder and a leading genetic cause of infant mortality. Advances in disease-modifying therapies have significantly improved outcomes when treatment is initiated early, underscoring the importance of timely diagnosis. With the growing availability of prenatal genetic screening and high-resolution molecular diagnostics, opportunities for early detection, and potentially in utero intervention, are rapidly expanding. This narrative review synthesizes current evidence on the prenatal management of SMA, focusing on diagnostic strategies, the clinical application of fetal genetic testing, and the emerging potential of fetal therapy. We explore both invasive and non-invasive diagnostic approaches and evaluate experimental prenatal treatment modalities, while critically addressing the associated ethical, regulatory, and economic considerations. As the field progresses, integrating in utero strategies into clinical care may reshape perinatal medicine and offer transformative potential for genetic neurodegenerative disorders diagnosed before birth. The convergence of early diagnosis, fetal intervention, and personalized genetic counseling will be central to optimizing care pathways and outcomes in the era of precision medicine. Although significant challenges remain, the translation of fetal therapy into routine clinical practice is approaching feasibility. Future clinical trials, anchored in definitive prenatal diagnosis, will be essential, with benefits potentially outweighing the inherent procedural risks.


  • Open Access

    The Preventive Power of the Mediterranean Diet Against Blue-Light-Induced Retinal Degeneration: Is the Secret in the Herbs and Spices?

    by Anja Harej Hrkać, Ana Pelčić, Tea Čaljkušić-Mance, Jasenka Mršić-Pelčić, Kristina Pilipović

    The Mediterranean diet, rich in plant-based foods, healthy fats, and herbs, has long been associated with a range of health benefits, including cardiovascular, neuroprotective, and anti-inflammatory effects. Recent studies suggest that certain components of this diet, particularly spices such as bay laurel, thyme, oregano, sage, and rosemary, may play a critical role in protecting the retina from oxidative damage, a key factor in blue-light-induced retinal degeneration. Blue light, emitted by digital screens and artificial lighting, has been implicated in the development of retinal conditions like age-related macular degeneration by inducing oxidative stress and inflammation. This review explores the potential of the herbs and spices commonly present in the Mediterranean diet to mitigate blue-light-induced retinal damage. These herbs are rich in polyphenols, flavonoids, essential oils, and terpenes, which offer antioxidant, anti-inflammatory, and antimicrobial properties, contributing to retinal health and reducing oxidative damage. By focusing on bioactive compounds such as eucalyptol (1,8-cineole), rosmarinic acid, carnosic acid, eugenol, and thymol, this article investigates how these herbs and spices might act as natural protectants against blue-light-induced stress and retinal degeneration. The findings highlight the promising role of these culinary staples in preventing retinal damage and offer insights into future dietary recommendations for eye health in an increasingly digital world.